Oramed Pharmaceuticals (ORMP) Long-Term Investments (2011 - 2026)

Oramed Pharmaceuticals (ORMP) has 16 years of Long-Term Investments data on file, last reported at $37.4 million in Q1 2026.

• Quarterly Long-Term Investments rose 5746.41% year-over-year to $37.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.4 million (up 5746.41% YoY) and the FY2025 annual result came in at $553000.0, down 98.41% from the prior year.
• Long-Term Investments grew to $37.4 million in Q1 2026, from $553000.0 in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $110.2 million in Q4 2023 to a low of $7000.0 in Q1 2023.
• A 5-year average of $14.8 million and a median of $2.7 million in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2023 — Long-Term Investments plunged 99.64% — and 2024, when it jumped 279100.0%.
• Tracing ORMP's Long-Term Investments over 5 years: stood at $2.7 million in 2022, then soared by 3981.04% to $110.2 million in 2023, then plunged by 68.41% to $34.8 million in 2024, then tumbled by 98.41% to $553000.0 in 2025, then jumped by 6666.18% to $37.4 million in 2026.
• The last three Long-Term Investments figures came in at $37.4 million (Q1 2026), $553000.0 (Q4 2025), and $28.5 million (Q3 2025), per Business Quant data.